JAC Advance Access published online on April 14, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg237
© 2003 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original article
1 Merck Research Laboratories, West Point, PA 19486-0004,
USA
* Corresponding author. E-mail: gailwoods{at}merck.com.
Received 3 December 2002
; revised 1 January 2003
; accepted 3 March 2003
Objective: The efficacy of ertapenem,
1 g once a day, for treatment of adults with serious infections
caused by Enterobacteriaceae was compared with ceftriaxone 1 g once
a day [complicated urinary tract infection (CUTI) and community-acquired
pneumonia (CAP)] or piperacillin-tazobactam, 3.375
g every 6 h (complicated intra-abdominal, complicated skin/skin
structure and acute pelvic infections). Patients and methods: This combined analysis
included the subgroup of all 1167 treated patients infected with
Enterobacteriaceae from seven randomized double-blind studies. Results: Escherichia coli was
the most common pathogen, accounting for 65.3% of all Enterobacteriaceae.
Among evaluable patients with deep tissue (intra-abdominal, skin
and pelvic) infections, the combined clinical cure rates were 84.8% (223
of 263) for ertapenem and 82.9% (194 of 234) for piperacillin-tazobactam [95% confidence
interval (CI) for the difference, adjusting for infection, -4.9% to
8.9%]. Cure rates by infection for ertapenem and
piperacillin-tazobactam, respectively, were: intra-abdominal,
85.1% (143 of 168) and 79.9% (119 of 149); pelvic, 86.8% (46
of 53) and 94% (47 of 50); skin/skin structure, 81% (34
of 42) and 80% (28 of 35). Among patients with CUTI, microbiological
cure rates were 90.5% (220 of 243) for ertapenem and 92% (196
of 213) for ceftriaxone (95% CI for the difference, -7.1% to
4.1%). In patients with CAP, clinical cure rates were 95% (19
of 20) for ertapenem and 88.9% (16 of 18) for ceftriaxone. Conclusion: Ertapenem therapy was as effective
as either piperacillin-tazobactam or ceftriaxone for serious
infections caused by Enterobacteriaceae.
Keywords: ertapenem, Enterobacteriaceae, Escherichia
coli, intra-abdominal infection, skin infection
Efficacy of ertapenem in the treatment of serious
infections caused by Enterobacteriaceae: analysis of pooled clinical
trial data
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Xiao, J. Siddiqui, and D. G. Remick Mechanisms of Mortality in Early and Late Sepsis Infect. Immun., September 1, 2006; 74(9): 5227 - 5235. [Abstract] [Full Text] [PDF]
|
|